News
  Date Title View
Mar 6, 2015
- Scott Canute, Former President of Global Manufacturing at Eli Lilly and Company and Subsequently at Genzyme Corporation, Appointed New Board Member -- Flexion CEO Michael Clayman Offers Thanks to Departing Board Member Andrew Schwab - BURLINGTON, Mass., March 6, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today...
Feb 24, 2015
BURLINGTON, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has completed enrollment in its pivotal Phase 2b confirmatory clinical trial designed to further evaluate the safety, tolerability and efficacy of FX006 as a treatment for relieving pain associated with OA of the knee. FX006 is Flex...
Feb 17, 2015
BURLINGTON, Mass., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the RBC Capital Markets Healthcare Conference on Tuesday, February 24, 2015 at 9:00 a.m. Eastern Time at The New York Palace Hotel in New York, NY. To ac...
Feb 2, 2015
BURLINGTON, Mass., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced dosing of the first patient in the Phase 3 clinical trial of its lead drug candidate FX006 as a treatment for pain associated with osteoarthritis (OA) of the knee. FX006 is Flexion's novel, non-opioid, sustained-release, intra-articular (IA ...
Dec 17, 2014
BURLINGTON, Mass., Dec. 17, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the closing of its previously announced underwritten public offering. A total of 5,796,000 shares of the Company's common stock were sold in the offering at a price to the public of $17.00 per share. The shares include 756,000 shares of com...
Dec 12, 2014
BURLINGTON, Mass., Dec. 12, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of its underwritten public offering of 5,040,000 shares of common stock at a price to the public of $17.00 per share. Flexion has also granted the underwriters a 30-day option to purchase up to an additional 756,000 shares of co...
Dec 8, 2014
BURLINGTON, Mass., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it is offering to sell 3,500,000 shares of common stock in an underwritten public offering. Flexion also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock in the p...
Dec 1, 2014
- Company Resumes Recruitment in Pivotal Phase 2b Trial; Initiation of Phase 3 Clinical Trial Planned for Early 2015- Conference Call Scheduled for Tomorrow, December 2, 2014 at 9:00 a.m. ET BURLINGTON, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (F...
Nov 17, 2014
BURLINGTON, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CFO Frederick Driscoll will present at the Stifel Healthcare Conference 2014 on Wednesday, November 19, 2014 at 2:25 p.m. Eastern Time. The conference will take place at the New York Palace Hotel in New York City. To access the liv...
Nov 13, 2014
Recent HighlightsFollowing meeting with U.S. Food & Drug Administration (FDA), announced plans to accelerate initiation of a Phase 3 clinical trial for FX006Bolstered intellectual property (IP) protection for FX006 Achieved progress in addressing questions related to FDA's clinical hold of FX006 BURLINGTON, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE...
FirstPrevious ...
10
... NextLast
= add release to Briefcase